Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	12.06	12.36	16.29	51.16	58.34	240.42
Short-Term Investments	105.57	126.98	193.24	277.67	189.33	135.41
Cash & Short-Term Investments	117.63	139.34	209.54	328.83	247.66	375.83
Cash Growth	-43.58%	-33.50%	-36.28%	32.77%	-34.10%	2255.87%
Accounts Receivable	0.23	0.07	0.27	0.15	0.2	1.15
Other Receivables	2.14	2.91	2.99	3.71	4.46	6.97
Total Trade Receivables	2.36	2.98	3.25	3.86	4.66	8.12
Other Current Assets	2.39	2.91	6.59	6.16	7.92	7.24
Total Current Assets	122.38	145.23	219.38	338.84	260.25	391.19
Net Property, Plant & Equipment	23.48	24.43	39.29	40.45	34.91	4.89
Long-Term Investments	1	3.51	49.13	51.33	77.07	45.3
Other Long-Term Assets	2.14	2.2	5.52	1.59	1.54	0.98
Total Assets	149	175.37	313.31	432.21	373.77	442.36
Accounts Payable	3.5	5.78	2.48	3.12	1.15	3.99
Accrued Expenses	13.89	16.54	23.62	21.14	16.08	13.14
Current Portion of Leases	1.29	1.2	1.43	1.2	0.97	-
Unearned Revenue	0.99	1.9	3.13	2.85	9.94	8.7
Total Current Liabilities	19.67	25.41	30.65	28.3	28.13	25.83
Long-Term Leases	25.66	26.03	25.06	25.91	26.78	2.1
Other Long-Term Liabilities	1.65	1.75	4.65	9.6	17.99	26.61
Total Long-Term Liabilities	27.31	27.78	29.71	35.51	44.77	28.7
Total Liabilities	46.98	53.19	60.36	63.81	72.89	54.53
Shareholders' Equity	102.02	122.18	252.95	368.4	300.87	387.83
Total Liabilities & Equity	149	175.37	313.31	432.21	373.77	442.36
Total Debt	26.95	27.23	26.49	27.11	27.75	2.1
Net Cash (Debt)	90.68	112.11	183.05	301.72	219.92	373.74
Net Cash Growth	-19.12%	-38.75%	-39.33%	37.20%	-41.16%	2500.08%
Net Cash Per Share	0.96	1.20	2.03	4.09	3.62	11.80

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q